The Career Development Program is designed to provide training and guidance for academic physicianscientists, clinician-investigators, and laboratory-based researchers who wish to dedicate their efforts to translational research in the areas of diagnosis, prevention, and treatment of ovarian cancer. Ours was one of the first ovarian SPOREs funded, and our Career Development Program has evolved as the general SPORE mechanism has changed and matured. The purpose of the Career Development Program is to support the development of young investigators who intend to focus their careers on translational studies of ovarian cancer. Our goal is for them to develop sufficient experience, with mentorship and appropriate educational opportunities, to attain external peer-reviewed funding in ovarian cancer research or to become Co-PIs on full SPORE projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083639-15
Application #
8731087
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
City
Houston
State
TX
Country
United States
Zip Code
77030
Umamaheswaran, Sujanitha; Dasari, Santosh K; Yang, Peiying et al. (2018) Stress, inflammation, and eicosanoids: an emerging perspective. Cancer Metastasis Rev 37:203-211
Wang, Jue; Zhao, Wei; Guo, Huifang et al. (2018) AKT isoform-specific expression and activation across cancer lineages. BMC Cancer 18:742
Huang, Yan; Hu, Wei; Huang, Jie et al. (2018) Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Mol Cancer Ther 17:464-473
Yang, Hailing; Mao, Weiqun; Rodriguez-Aguayo, Cristian et al. (2018) Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res 24:5072-5084
Rhyasen, Garrett W; Yao, Yi; Zhang, Jingwen et al. (2018) BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS One 13:e0200826
Chen, Jian; Zaidi, Sobia; Rao, Shuyun et al. (2018) Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor-? Pathway. Gastroenterology 154:195-210
Sun, Chaoyang; Yin, Jun; Fang, Yong et al. (2018) BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33:401-416.e8
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Jung, Youn-Sang; Wang, Wenqi; Jun, Sohee et al. (2018) Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via ?-catenin. Nat Cell Biol 20:1303-1314
Jung, Youn-Sang; Jun, Sohee; Kim, Moon Jong et al. (2018) TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/?-catenin signalling. Nat Cell Biol 20:1421-1433

Showing the most recent 10 out of 648 publications